William Blair analyst Andrew Brackmann has reiterated their neutral stance on CDNA stock, giving a Hold rating on November 1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Brackmann has given his Hold rating due to a combination of factors impacting CareDx’s financial outlook. The company reported mixed results in its third-quarter update, with revenue and volumes falling slightly short of expectations, primarily due to lower-than-anticipated kidney transplant volumes and complexities related to prior-period collections. However, there are promising signs from CareDx’s revenue cycle management initiatives, which are beginning to show success and offer potential for future revenue growth.
Despite these positive developments, there are still uncertainties, particularly regarding the draft LCD, which remains a significant concern and could affect the company’s financial model. Clarity on this issue is not expected until early 2026, making it challenging to justify an upgrade in the stock rating at this time. While there are growth drivers in place, such as the integration with Epic Aura, the lack of immediate clarity on regulatory matters leads to the decision to maintain a Hold rating until more information becomes available.
Brackmann covers the Healthcare sector, focusing on stocks such as Exact Sciences, Veracyte, and Hologic. According to TipRanks, Brackmann has an average return of 32.3% and a 68.09% success rate on recommended stocks.
In another report released on November 1, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $15.50 price target.